✦ LIBER ✦

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

✍ Scribed by Swain, Sandra M; Kim, Sung-Bae; Cortés, Javier; Ro, Jungsil; Semiglazov, Vladimir; Campone, Mario; Ciruelos, Eva; Ferrero, Jean-Marc; Schneeweiss, Andreas; Knott, Adam; Clark, Emma; Ross, Graham; Benyunes, Mark C; Baselga, José

Book ID: 120263605
Publisher: The Lancet
Year: 2013
Tongue: English
Weight: 399 KB
Volume: 14
Category: Article
ISSN: 1470-2045
DOI: 10.1016/S1470-2045(13)70130-X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of older patients with HER2-po

Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)

✍ Miles, David; Baselga, José; Amadori, Dino; Sunpaweravong, Patrapim; Semiglazov, 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 282 KB

Incidence of central nervous system meta

Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA

✍ Swain, S. M.; Baselga, J.; Miles, D.; Im, Y.- H.; Quah, C.; Lee, L. F.; Cortes, 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 145 KB

Everolimus for women with trastuzumab-re

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

✍ André, Fabrice (author);O'Regan, Ruth (author);Ozguroglu, Mustafa (author);Toi, 📂 Article 📅 2014 🏛 Lancet Publishing Group 🌐 English ⚖ 478 KB

Everolimus for women with trastuzumab-re

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

✍ André, Fabrice (author);O'Regan, Ruth (author);Ozguroglu, Mustafa (author);Toi, 📂 Article 📅 2014 🏛 Lancet Publishing Group 🌐 English ⚖ 478 KB

Motesanib, or open-label bevacizumab, in

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

✍ Miguel Martin; Henri Roche; Tamas Pinter; John Crown; M John Kennedy; Louise Pro 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 230 KB

705 ABIRATERONE ACETATE PLUS LOW-DOSE PR

705 ABIRATERONE ACETATE PLUS LOW-DOSE PREDNISONE HAS A FAVORABLE SAFETY PROFILE, IMPROVES SURVIVAL AND PRODUCES PSA AND RADIOGRAPHIC RESPONSES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PROGRESSING AFTER DOCETAXEL-BASED CHEMOTHERAPY: RESULTS FROM COU-AA-301, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III STUDY

✍ Saad, Fred; de Bono, Johann S.; Haqq, Christopher M.; Logothetis, Christopher J. 📂 Article 📅 2011 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 56 KB